Kornimate/medical-research-clean huggingface dataset:
patient education videos to improve patients' experience during radiotherapy treatment: a national project

Conditions: Cancer, Breast; Cancer, Lung; Cancer Prostate; Cancer Head Neck; Cancer, Gastrointestinal

Summary: patients often base their information on the experiences of other patients or on information they find on the internet. this information is in many cases incorrect, outdated or not applying to the patient's situation. this leads to misconceptions or inappropriate anxiety. during the intake consultation at the radiotherapy department, doctors, nurses and rtts provide accurate and patient-specific information, but it can be overwhelming and it is known that only part of this information is remembered. moreover, it remains difficult for a patient to imagine how the treatment will proceed. the combination of verbal information, supplemented with video material, seems to be the ideal way to convey information. after all, a video can be viewed again afterwards, possibly together with loved ones, or can be shown in advance in preparation of the consultation. in belgium, the existence of patient education videos about radiotherapy is very limited. making these kinds of videos is expensive and time consuming. for that reason, bestro (belgian society for radiotherapy and oncology) started a project to make videos for patients that can be used nationally by all radiotherapy centers. the project is sponsored by foundation against cancer.

a first video illustrating the general radiotherapy process is already available. this video will be used as a 'test video' to be shown to patients undergoing radiotherapy in one of the 4 participating centers. questionnaires will evaluate the quality and the impact of the video and will assess the need for additional information. moreover, 25 patients will be invited to participate in 5 focus groups, each focus group concentrating on one of the 5 most frequent tumor groups (breast tumors, lung tumors, head and neck tumors, urological tumors and gastro-intestinal tumors). the information gathered from the questionnaires and focus groups will be used to determine the content and format of the next videos. in total, about 10 videos on specific parts of the radiotherapy process will be produced.

Eligibility criteria:
inclusion criteria: * diagnosis of cancer, * age ≥ 18 years, * undergoing radiotherapy as part of their treatment exclusion criteria: - history of previous radiation treatment
comparison studies comparing hemodynamic parameters provided by the caretaker against respective gold standard references

Conditions: Cardiac Output, Low

Summary: comparison studies comparing hemodynamic parameters provided by the caretaker against respective gold standard references.

comparison study comparing hemodynamic parameters provided by the caretaker against respective gold standard references. specifically, continuous beat-by-beat blood pressure readings against arterial catheter readings and cardiac output (co) and stroke volume (sv) measures against thermo-dilution measurements

Eligibility criteria:
inclusion criteria: * 18 years of age * able and willing to participate * provide written consent exclusion criteria: * unable to give written consent * \<18 years of age * no or poor finger pulse, as determined through visual inspection for ischemic hands
chronomodulated chemotherapy followed by concurrent chemo-radiotherapy with imrt in the treatment of advanced nasopharyngeal cancer

Conditions: Esophageal Neoplasms

Summary: 1. observe and compare the chrono-chemotherapy imrt and conventional chemotherapy and intensity modulated radiotherapy term efficacy of the treatment of locally advanced nasopharyngeal carcinoma. 2. evaluation chrono-chemotherapy imrt and conventional chemotherapy and intensity modulated radiotherapy in locally advanced nasopharyngeal carcinoma safety and tolerability. 3）observing the adverse reaction and effects of two groups,expected chrono-chemotherapy group can achieve lower toxicity, improve the curative effect, for the treatment of nasopharyngeal carcinoma provides a more reasonable way.


Eligibility criteria:
inclusion criteria: * initial treatment of advanced nasopharyngeal carcinoma ⅲ-ⅳ patients with pathologically confirmed (according to 2010 uicc staging, t3-4, n0-3), without evidence of distant metastasis (m0). have measurable tumor lesions. * kps≥70 points. * the age of 18-70 years old, male or female. * no major organ dysfunction; normal bone marrow function (wbc ≥4.0 × 109 / l, platelets ≥100 × 109 / l, hemoglobin ≥90g / l), normal liver function (total bilirubin, alanine aminotransferase, aspartate aminotransferase ≤1.5 times the upper limit of normal), normal renal function (creatinine ≤ 1.5 times upper limit of normal). * understand this study and signed informed consent. exclusion criteria: * distant metastasis. * who had received prior chemotherapy. * patients have physical or mental illness, and by researchers believe that patients can not be completely or fully understood in this study possible complications. * pregnancy (via the urine or serum β-hcg test confirmed) or during lactation. * serious complications, such as uncontrolled hypertension, heart failure, diabetes and so on.

Keywords: chronomodulated chemotherapy intensity modulated radiation therapy advanced nasopharyngeal cancer
comparison of different methods for intra- and postoperative pain therapy in thoracic surgery

Conditions: Thoracic Surgery

Summary: the aim of the study is to determine which regional anaesthesiological technique (thoracic epidural analgesia or paravertebral block) is more suitable for thoracic surgery

thoracic interventions (lung operations) are associated with considerable postoperative pain, whereby an open surgical procedure via a skin incision (thoracotomy) is more painful than a minimally invasive endoscopic intervention (thoracoscopy). in order to reduce pain, a regional anaesthetic is administered during the induction of anaesthesia, which reduces pain both intraoperatively and postoperatively. in thoracic surgery, thoracic epidural analgesia (pda) and paravertebral block (pvb) are the main regional anaesthesiological measures used, although it is unclear which of the two procedures is superior in terms of efficiency and effectiveness. particularly intraoperatively, but also to some extent postoperatively, regional anaesthesia alone is usually not sufficient for pain management. rather, additional systemic (i.e. intravenous) analgesics (especially opioids) are administered. therefore, the amount of these additionally administered analgesics is a measure of the efficiency of the regional anaesthesia procedure.

Eligibility criteria:
inclusion criteria: * elective thoracic surgery * american society of anaesthesiologists (asa) 1-3 status * written informed consent exclusion criteria: * pregnancy * adipositas (bmi \> 30) * cardiac arrhythmia * coagulation abnormalities * chronic pain * opiate abuses

Keywords: thoracic surgery paravertebral block epidural analgesia thoracic anaesthesia
selatogrel outcome study in suspected acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: this study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (thygesen et al. 2018) and having additional cardiovascular risk factors.

the purpose of this study is to assess the clinical efficacy of selatogrel when self-administered upon occurrence of symptoms suggestive of an acute myocardial infarction (ami) in participants at risk of having a recurrent ami.

Eligibility criteria:
main inclusion criteria: * confirmed diagnosis of symptomatic type 1 acute myocardial infarction (ami) st-elevation myocardial infarction (stemi) or non-st-elevation myocardial infarction (nstemi), no longer than 4 weeks prior to randomization. * diagnosis of multivessel coronary artery disease defined as ≥ 50% stenosis on 2 or more coronary artery territories, including the left main artery, during a prior cardiac catheterization or cardiac catheterization during the qualifying ami event and presence of at least 1 of the following risk factors: * second prior ami, * diabetes mellitus defined by ongoing glucose lowering treatment, * chronic kidney disease defined as estimated glomerular filtration rate less than 60 ml/min/1.73 m2 and either known history of chronic kidney disease or a biomarker of chronic kidney damage, * peripheral artery disease at any time prior to randomization, * absence of, or unsuccessful coronary revascularization of the qualifying ami. * successful self-administered placebo according to the autoinjector instruction for use training during screening. main exclusion criteria: * increased risk of serious bleeding including any of the following: * history of intracranial bleed at any time. * known uncorrected intracranial vascular abnormality. * gastrointestinal bleed requiring hospitalization or transfusion within 1 year prior to screening. * already on oral triple antithrombotic therapy (i.e., dual antiplatelet therapy and oral anticoagulant). * known liver impairment significantly affecting the hepatic function. * current dialysis. * ischemic stroke or transient ischemic attack within 3 months of screening. * chronic anemia with hemoglobin \< 10 g/dl. * chronic thrombocytopenia with platelet count \< 100,000/mm3. * known hypersensitivity to selatogrel, any of its excipients, or drugs of the p2y12 class. * previous exposure to an investigational drug within 3 months prior to randomization. * participation in another clinical trial with an investigational product or device within 3 months prior to randomization.

Keywords: platelet aggregation inhibitors
registry of phacoemulsification for cataract surgery

Conditions: Cataract

Summary: cataracts cause vision loss due to opacities in the lens. cataract surgery is performed by emulsifying the nucleus of the lens. a phacoemulsifier is the machine used to deliver ultrasonic energy in the eye to fragment the lens and aspirate the debris. in contrast to the large number of cataract procedures performed worldwide, there is surprisingly scarce data regarding the intraoperative parameters used during phacoemulsification. as new technologies are made available to surgeons, this impedes a large-scale analysis of the benefits of the advances in phacoemulsifiers. the investigators aim to establish a nationwide registry with a database of intraoperative data recorded during the cataract procedures performed with the centurion phacoemulsifier. the data collected would encompass all parameters recorded in the phacoemusifiers' logs, such as the energy delivered in the eye (longitudinal, torsional and other), us time, bss volume, duration of the procedure, surgeon settings and others. the objective will be to capture data from at least 100,000 procedures/year.

a nationwide registry will be established with a database of intraoperative data recorded during the cataract procedures performed with the centurion phacoemulsifiers. the following intraoperative parameters used during the cataract surgery will be recorded and analyzed: primary endpoint: ultrasound time (us time) exploratory endpoints: * cde : cumulated dissipated energy * total surgery time * bbs volume * torsional and longitudinal energy * iop settings * vacuum settings procedures performed with the active sentry module - where a pressure sensor is built in the phacoemulsifier handpiece will be compared to other to procedures performed without this module. data will be collected and analyzed from centurions cases log extracted from at least 200 centurions installed in france. parameter and settings will be retrospectively analyzed. a direct extraction of data from the machines will be processed for the analyses. no patient demographic data will be recorded. the objective will be to capture data from at least 100,000 procedures and to run data analyses on a nationwide scale. the database will serve as a basis to assess the technological advances aimed at reducing the amount of energy delivered in the eye, the duration of ultrasound use and overall the duration of procedures.

Eligibility criteria:
inclusion criteria: - all procedures recorded in centurions (200 machines). exclusion criteria: * opposition of the center to data collection. * complicated surgery (e.g. anterior vitrectomy) identified as such in the event log

Keywords: cataract surgery phacoemulsification
myeloid-derived suppressor cells in colorectal cancer

Conditions: Colorectal Cancer; Suppression; Complication,Postoperative; Radiotherapy

Summary: the aim of the study is to evaluate whether the preoperative level of myeloid-derived suppressor cells is associated with postoperative complications classified by clavien-dindo categories. levels of all mdsc, polymorphonuclear mdsc (pmnmdsc), monocytic mdsc (mmdsc), early-stage mdsc (emdsc) and monocytic to polymorphonuclear mdsc ratio (m/pmn mdcs) were established and compared in patients with postoperative complications, severe postoperative complications (\>= iiia according to clavien-dindo) and severe septic complications.

levels of all mdsc, polymorphonuclear mdsc (pmnmdsc), monocytic mdsc (mmdsc), early-stage mdsc (emdsc) and monocytic to polymorphonuclear mdsc ratio (m/pmn mdcs) were established and compared in patients with and without postoperative complications. then subgroup analysis was performed to compare levels of mdsc in patients with severe postoperative complications (\>= iiia according to clavien-dindo) and those without severe complications. another subgroup analysis will be performed for patients with severe septic complications that are defined as severe complications with accompanying infection. levels of mdsc will be compared by means of u mann whitney test as their distribution is not normal. after above mentioned analyses it will be possible to evaluate the role of mdsc in patients with colorectal cancer in terms of postoperative complications. additional analyse will be performed to compare levels of mdsc in patients who underwent neoadjuvant treatment (radiotherapy or chemoradiotherapy).

Eligibility criteria:
inclusion criteria: * age ≥ 18 * colorectal cancer confirmed by histological examination of biopsy specimen * elective operation * signed informed consent exclusion criteria: * age \< 18 * pregnancy or lactation * emergency operation * general condition that precludes understanding and signing of the informed consent form
a study to evaluate safety, efficacy, and tolerability of tez/iva in orkambi® (lumacaftor/ivacaftor) -experienced subjects with cystic fibrosis (cf)

Conditions: Cystic Fibrosis

Summary: study vx16-661-114 (study 114) is a phase 3b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in subjects aged 12 years and older with cf who are homozygous for the f508del mutation on the cystic fibrosis transmembrane conductance regulator gene (cftr) gene and who discontinued treatment with orkambi due to respiratory symptoms considered related to treatment. this study is designed to evaluate the safety and efficacy of tezacaftor/ivacaftor (tez/iva).


Eligibility criteria:
inclusion criteria: * willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures. * prior discontinuation of orkambi, with at least 1 respiratory sign or symptom considered related to therapy. * resolution or stabilization of qualifying event(s) \>28 days prior to screening. * discontinuation of orkambi therapy must have occurred within approximately 12 weeks from the first dose of orkambi. * homozygous for f508del mutation in the cftr gene as documented in the subject's medical record. if genotype documentation is not available in the medical record, genotyping will be performed during screening. * fev1 ≥25% and ≤90% of predicted normal for age, sex, and height. * stable cf disease as judged by the investigator. * other protocol defined inclusion criteria could apply. exclusion criteria: * history of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. * recent rapid or progressive deterioration in respiratory status. * receiving continuous oxygen at \>2l/min or on face-mask ventilation. * any protocol-defined exclusionary laboratory values at screening. * child-pugh class b or c hepatic impairment. * an acute upper or lower respiratory infection, pulmonary exacerbation, or change in therapy for pulmonary disease within 28 days before day 1. * documentation of colonization with organisms associated with a more rapid decline in pulmonary status. * history of lung transplantation since most recent initiation of orkambi. * history of alcohol or drug abuse in the past year as deemed by the investigator. * participation in an investigational drug study or use of a cftr modulator within 28 days or 5 terminal half-lives of the investigational drug or modulator (whichever is longer). * use of restricted medications or foods within the specified window before the first dose of study drug, or an anticipated need or use of restricted medication or foods after the first dose of study drug. * pregnant or nursing females: females of child-bearing potential must have a negative pregnancy test at screening and day 1. * other protocol defined exclusion criteria could apply.
postoperative pain after ambulatory arthroscopic shoulder surgery

Conditions: Chronic Postoperative Pain

Summary: shoulder disorders are frequent, often associated with pain and occur in 7-34% of the general population and in 21% of the elderly population. of particular interest is prediction of postoperative pain after outpatient arthroscopic shoulder surgery since the clinical experience is that surgery does not always provides pain relief and the interindividual variation in acute postoperative pain intensity is significant. in addition, a swedish study has shown that shoulder operations are associated with longer convalescence than other orthopaedic outpatient surgeries.

this study is a prospective cohort with 6 months follow-up. patients receive 5 questionnaires (preoperatively, 24 hours, 1 week, 3 months, 6 months, 1 and 2 years after surgery). the questionnaires contain questions about: * preoperative shoulder pain (type, intensity and duration) * preoperative pain in other areas besides the shoulder * brief pain inventory (bpi) * western ontario rotator cuff index (worc) * single assessment numeric evaluation (sane) * 3 validated physiological questionnaires: * state trait anxiety (stai) * pain catastrophizing scale (pcs) * hospital anxiety and depression scale (hads) in addition a cold pressor test is performed on the day of surgery to test the patients' threshold and ability to repress pain.

Eligibility criteria:
inclusion criteria: * arthroscopic shoulder surgery (subacromial decompression and acromioclavicular joint resection). exclusion criteria: * • \< 18 years * mental disorders * unable to speak and/or read danish * shoulder surgery within the last year * raynauds phenomenon * cuff suture * biceps tenodesis * labrum suture
optimal timing of zoster vaccine after hematopoietic stem cell transplantation

Conditions: Herpes Zoster

Summary: the purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patient aged over 50 with history of hematopoietic stem cell transplantation(hsct).

due to lack of data on safety of live vaccine in the recipient of hematopoietic stem cell transplantation, cibmtr(center for international blood and marrow transplant research) guidelines recommend varicella vaccination only in patients who is at least two years after transplantation and without graft versus host disease and no immunosuppressive drug. however, recent studies have demonstrated the safety and efficacy of shingles vaccination in patients receiving hematopoietic stem cell transplantation. but, there is no basis for timing of live vaccine administration after hsct. the investigators plan to make scientific recommendation for optimal timing of zoster vaccine after hsct by comparing immune response between two groups(vaccination at 2 to 5years after hsct vs. 5 to 10years after hsct). primary outcome is interferon gamma releasing elispot response at week 6 after vaccination. secondary outcome is elisa titer for zoster-specific igg at week 6 after vaccination. all the patients will be asked if they have any contraindication for zoster vaccine by a physician before vaccination. and they will be monitored for any adverse reaction of the vaccination after 6 weeks(visiting the hospital). in order to confirm the efficacy of the experiment, 30 healthy controls and 30 patients who were treated with chemotherapy alone for leukemia were selected. the control group will also apply the same protocol as above.

Eligibility criteria:
inclusion criteria: * adults aged 50 years or older who is at least 2 years after hematopoietic stem cell transplantation (experimental group) * adults aged 50 years or older who is at least 6 months after being cured by chemotherapy for leukemia (control group) * healthy adults aged 50 years or older who do not meet exclusion criteria (control group) * adults who can understand and agreed with the informed consents exclusion criteria: * adults who have conditions which is contraindication for zoster vaccine * adults who take immunosuppressant * adults with graft versus host disease(gvhd) * adults who take antivirals agent * adults who experienced vzv infection after hematopoietic stem cell transplantation * adults who received vzv vaccination already after hematopoietic stem cell transplantation * adults who are not eligible for zoster vaccination by investigator's assessment

Keywords: herpes zoster vaccine cell-mediated immunity hematopoietic stem cell transplantation